At Aro, we’re developing a patented platform technology called Centyrins that are uniquely positioned to achieve precise targeting of diverse therapeutic payloads to specific cells of interest. Centyrins are small protein domains based on the fibronectin domains of human Tenascin C that combine the affinity and specificity properties of antibodies with the stability and tissue penetration properties of small molecules.
Our efforts are focused on discovering and developing Centyrin-oligonucleotide conjugate therapies that are meant to address one of the greatest challenges facing oligonucleotide-based medicines today: targeted delivery of oligonucleotides to extra-hepatic tissues.
Led by an experienced and extraordinary team, Aro is backed by an exceptional syndicate that supports our commitment to advancing drug candidates with the potential to improve patient’s lives and to building an ideal environment for scientific and leadership growth.
We are growing our team in multiple areas--even if you don't see a current role that is a match for you, we'd love to connect. Share your CV and we'll be sure to be in touch if a new opportunity arises with our company! We are seeking Scientists (BS/MS), Investigators (PhD) focused in protein engineering, oligonucleotide synthesis, molecular and in-vivo biology and bioconjugation, along with future openings in translational and clinical development.
What We Do
Unlocking the Potential of Genetic Medicines
Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.
